Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 12/20 | 0.61 |
| ▸ | ACHE | P22303 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8971273 | 0.96 | HTR4 (0.61) | HTR4ACHEMEN1ALDH1A1CYP2D6 | |
| SCHEMBL16403622 | 0.83 | HTR4 (0.59) | HTR4ACHEMEN1ALDH1A1CYP2D6 | |
| SCHEMBL7254150 | 0.82 | HTR4 (0.45) | HTR4ACHEMEN1ALDH1A1CYP2D6 | |
| SCHEMBL4437515 | 0.82 | HTR4 (0.54) | HTR4ACHEMEN1ALDH1A1CYP2D6 | |
| SCHEMBL22022521 | 0.80 | HTR4 (0.68) | HTR4ACHEMEN1ALDH1A1CYP2D6 | |
| SCHEMBL549019 | 0.76 | HTR4 (1.00) | HTR4ACHEMEN1ALDH1A1CYP2D6 | |
| SCHEMBL29604454 | 0.76 | HTR4 (1.00) | HTR4ACHEMEN1ALDH1A1CYP2D6 | |
| SCHEMBL3230370 | 0.76 | HTR4 (0.64) | HTR4ACHEMEN1ALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL8973729 | 0.75 | HTR4 (0.63) | HTR4ACHEMEN1ALDH1A1CYP2D6 | |
| SCHEMBL506210 | 0.75 | HTR4 (0.78) | HTR4ACHEMEN1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020237096-A1 | COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT | ARDELYX, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| EP-3030252-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015021358-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | CHARMOT DOMINIQUE (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| EP-2240445-A1 | NOVEL SALT OF TEGASEROD | Generics (UK) Limited (GB) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010099217-A1 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS | BRAINCELLS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010015794-A1 | NOVEL POLYMORPHIC FORMS OF TEGASEROD | GENERICS [UK] LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| EP-2125017-A2 | MODULATION OF NEUROGENESIS WITH USE OF MODAFINIL | Braincells, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009141573-A1 | NOVEL POLYMORPH OF TEGASEROD ADIPATE | GENERICS [UK] LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141571-A1 | NOVEL POLYMORPH OF TEGASEROD HYDROCHLORIDE | GENERICS [UK] LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2007134136-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1853256-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006083710-A2 | USE OF 5-HT4 AGONIST FOR TREATING DELAYED GASTRIC EMPTYING WHICH MAY BE INDUCED BY A PROTON PUMP INHIBITOR | NOVARTIS AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| EP-1385476-A4 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS SINAI MEDICAL CENTER (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1385476-A2 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS-SINAI MEDICAL CENTER (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083926-A2 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS-SINAI MEDICAL CENTER (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | disclosed |